Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 18/20 | 0.74 |
| ▸ | RXRA | P19793 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | VHL | P40337 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347555 | 1.00 | NR1H3 (0.74) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL14445853 | 1.00 | NR1H3 (0.74) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL5349211 | 0.99 | NR1H3 (0.74) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL5349225 | 0.99 | NR1H3 (0.74) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL5359665 | 0.94 | NR1H3 (0.84) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL5349204 | 0.93 | NR1H3 (0.85) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4947481 | 0.93 | NR1H3 (0.86) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL3857876 | 0.93 | NR1H3 (0.86) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL3857872 | 0.93 | NR1H3 (0.86) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL6439583 | 0.92 | NR1H3 (0.86) | NR1H3NR1H2RXRAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | claimed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | claimed |
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1497270-A4 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | disclosed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107444-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | NR1H3 2/4885NR1H2 1/4885RXRA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.